Sp1

Mantle cell lymphoma is a rare and aggressive type of non-Hodgkin lymphoma originating from B-cells in the "mantle zone" of the lymph nodes. The development of novel targeted therapies and immunotherapies, such as Bruton's tyrosine kinase (BTK) inhibitors, is improving treatment outcomes and driving market growth for Mantle cell lymphoma. LAS VEGAS, Sept. 19, 2024 /PRNewswire/ -- DelveInsight's ' Mantle Cell Lymphoma Pipeline Insight 2024 ' report provides comprehensive global coverage of pipeline mantle cell lymphoma therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the mantle cell lymphoma pipeline domain. Key Takeaways from the Mantle Cell Lymphoma Pipeline Report DelveInsight's mantle cell lymphoma pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for mantle cell lymphoma treatment. Key mantle cell lymphoma companies such as AbbVie, Adicet Bio, InnoCare Pharma Inc., Guangzhou Lupeng Pharmaceutical Company LTD., BeiGene, Nurix, LegoChem Biosciences, Xynomic Pharmaceuticals, Merck & Co, Incyte Corporation, TG Therapeutics, Janssen/Pharmacyclics, Eternity Bioscience, Traws Pharm, Advenchen Laboratories, and others are evaluating new mantle cell lymphoma drugs to improve the treatment landscape. Promising mantle cell lymphoma pipeline therapies such as Venetoclax, ADI-001, Orelabrutinib, LP-168, BGB-11417, NX 2127, LCB 71, NX 5948, Abexinostat, Pembrolizumab, Parsaclisib, Umbralisib, Ibrutinib, Edralbrutinib, Narazaciclib, Lucitanib, and others are under different phases of mantle cell lymphoma clinical trials. In May 2024, AstraZeneca had announced positive interim results from the Phase III ECHO clinical trial, which evaluated Bruton's tyrosine kinase (BTK) inhibitor Calquence (acalabrutinib) in combination with standard chemoimmunotherapy for treating mantle cell lymphoma (MCL). In March 2024, BeiGene, Ltd. announced the presentation of emerging oncology pipeline data at the American Association for Cancer Research (AACR) Annual Meeting. Additional highlights include preclinical characterization data for an investigational BTK degrader, BGB-16673, currently in clinical development for B-cell malignancies, including mantle cell lymphoma In October 2023, Ascentage Pharma announced that it has entered into a clinical collaboration with AstraZeneca Investment. The two companies will jointly conduct a registrational Phase III study of the Bcl-2 inhibitor, APG-2575 (lisaftoclax), in combination with AstraZeneca's Bruton's tyrosine kinase (BTK) inhibitor, CALQUENCE® (acalabrutinib), in treatment-naive patients with first-line chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). In January 2023, the FDA granted an orphan drug designation to LP-284, a novel small-molecule, next-generation acylfulvene, for the treatment of mantle cell lymphoma (MCL), a rare and aggressive form of B-cell non-Hodgkin lymphoma (NHL), according to an announcement from Lantern Pharma. Request a sample and discover the recent advances in mantle cell lymphoma treatment drugs @ Mantle Cell Lymphoma Pipeline Report The mantle cell lymphoma pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage mantle cell lymphoma drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the mantle cell lymphoma clinical trial landscape. Mantle Cell Lymphoma Overview Mantle cell lymphoma (MCL) is a rare subtype of B-cell non-Hodgkin lymphomas (NHLs) characterized by the (11,14) translocation, leading to overexpression of the cyclin D1 (CCND1) gene. Its various morphological variants can make diagnosis challenging, though some cases are straightforward. Many individuals with MCL are asymptomatic in the early stages, but may later seek medical attention due to persistent, typically painless swelling of lymph nodes, especially in the neck and throat region (e.g., Waldeyer's ring). MCL is marked by a reciprocal chromosomal translocation t(11;14)(q13;q32), which places the cyclin D1 gene next to the immunoglobulin heavy chain gene, causing continuous cyclin D1 expression. This overexpression contributes to tumor cell proliferation through cell cycle dysregulation, chromosomal instability, and epigenetic changes. Rarely, MCL cases without this translocation may involve CCND2 or CCND3 translocations. Hypothetical molecular subtypes, based on the cell of origin, correlate with clinical phenotypes: classical or aggressive MCL arises from naive B cells lacking or having limited iGVH mutations and expressing SOX11, a neural transcription factor inhibiting terminal B cell differentiation. The indolent variant originates from antigen-experienced B cells with IGVH somatic hypermutations, typically SOX11-negative and genetically stable. Diagnosis of MCL involves detailed patient history, thorough clinical evaluation, and specialized tests, including biopsy of an affected lymph node or bone marrow. These tests confirm the NHL type and subtype, assess disease extent, and determine appropriate treatments. Treatment for MCL is multifaceted and tailored to each patient, often including chemotherapy, immunotherapy drugs like rituximab, targeted therapies such as ibrutinib, and stem cell transplants, particularly for aggressive disease or younger patients. Radiation therapy may target specific lymphoma areas. Participation in clinical trials can offer new treatment options. Treatment plans are developed collaboratively by healthcare professionals and patients, considering disease stage, overall health, and personal preferences. Regular monitoring and follow-up care are essential to track treatment response and manage side effects effectively. Find out more about mantle cell lymphoma treatment drugs @ Drugs for Mantle Cell Lymphoma Treatment A snapshot of the Mantle Cell Lymphoma Pipeline Drugs mentioned in the report: Learn more about the emerging mantle cell lymphoma pipeline therapies @ Mantle Cell Lymphoma Clinical Trials Mantle Cell Lymphoma Therapeutics Assessment The mantle cell lymphoma pipeline report proffers an integral view of the mantle cell lymphoma emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration. Scope of the Mantle Cell Lymphoma Pipeline Report Coverage: Global Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Therapeutics Assessment By Route of Administration: Oral, Parenteral, Intravenous, Subcutaneous, Topical Therapeutics Assessment By Molecule Type: Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy Therapeutics Assessment By Mechanism of Action: Apoptosis stimulants, Proto-oncogene protein c-bcl-2 inhibitors, Proteasome inhibitors, Immunologic cytotoxicity, T lymphocyte replacements, Agammaglobulinemia tyrosine kinase inhibitors Key Mantle Cell Lymphoma Companies: AbbVie, Adicet Bio, InnoCare Pharma Inc., Guangzhou Lupeng Pharmaceutical Company LTD., BeiGene, Nurix, LegoChem Biosciences, Xynomic Pharmaceuticals, Merck & Co, Incyte Corporation, TG Therapeutics, Janssen/Pharmacyclics, Eternity Bioscience, Traws Pharm, Advenchen Laboratories, and others Key Mantle Cell Lymphoma Pipeline Therapies: Venetoclax, ADI-001, Orelabrutinib, LP-168, BGB-11417, NX 2127, LCB 71, NX 5948, Abexinostat, Pembrolizumab, Parsaclisib, Umbralisib, Ibrutinib, Edralbrutinib, Narazaciclib, Lucitanib, and others Dive deep into rich insights for new drugs for mantle cell lymphoma treatment, visit @ Mantle Cell Lymphoma Drugs Table of Contents For further information on the mantle cell lymphoma pipeline therapeutics, reach out @ Mantle Cell Lymphoma Treatment Drugs Related Reports B-Cell Lymphoma Epidemiology B-Cell Lymphoma Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the B-cell lymphoma epidemiology trends. B-Cell Lymphoma Market B-Cell Lymphoma Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key B-cell lymphoma companies, including Vincerx Pharma, Ubix Therapeutics, Biomea Fusion Inc, Shanghai Hengrui Pharmaceutical, BeiGene, Hanmi Pharmaceutical, among others. Diffuse Large B-Cell Lymphoma Pipeline Diffuse Large B-Cell Lymphoma Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key DLBCL companies, including Genmab, Roche, Acerta Pharma, Autolus, Xynomic Pharmaceuticals, Genentech, Celgene, AbbVie, Mabion, among others. Diffuse Large B-Cell Lymphoma Market Diffuse Large B-Cell Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key B-cell lymphoma companies, including AbbVie, Genmab, Merck, Roche, Xencor and Janssen, Denovo Biopharma, Calithera Biosciences, IMV, Biogen, Autolus Therapeutics, Allogene Therapeutics, Novartis, Miltenyi Biomedicine, Regeneron Pharmaceuticals, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

双样本孟德尔随机化（MR）分析结果表明，Akkermansia与高度近视存在显著的因果关系，Akkermansia作为保护因子，其定植丰度与眼轴长度呈负相关。 复旦大学附属眼耳鼻喉科医院竺向佳、卢奕等人通过对高度近视患者的肠道微生物和代谢物进行深入分析，发现益生菌Akkermansia的定植以及肠菌代谢物吲哚-3-乙酸（3-IAA）的水平与近视的发展程度紧密相关。 他们利用小鼠实验揭示3-IAA可以促进巩膜中主要的结构蛋白质表达，即I型胶原蛋白，这意味着3-IAA有助于维持巩膜的结构完整性。每日补充3-IAA可以帮助高度近视小鼠阻止或减缓由于巩膜结构重构导致的近视进展，这为开发新型近视预防和治疗策略提供了可能。论文于近日刊登在Cell Discovery期刊上[1]。 论文首页截图 高度近视（HM）定义为等效球镜度数≤-6.00 D或眼轴长度（AL）≥ 26 mm，患者患青光眼、白内障、黄斑变性的风险较高。传统上人们往往只关注高度近视对眼睛本身的影响，比如视力下降和眼部结构的改变，而忽略了高度近视可能与身体其他系统功能失调之间的关系，这在很大程度上限制了寻找有效的干预措施。 巩膜中的细胞外基质（ECM）发生重塑，特别是关键成分I型胶原蛋白的改变，会削弱巩膜的结构框架，导致巩膜变薄和眼轴过度延长，从而诱发高度近视。正巧在过去二十年间，肠菌被发现对于多种疾病中的胶原蛋白重塑和纤维化有着显著影响，比如恢复健康肠菌可以防止小鼠的心脏过度纤维化，并在压力条件下恢复细胞外基质的完整性，或是特定类型肠菌的定植可以改善小鼠的肾脏纤维化。 因此，类似于脑-肠轴，已有研究提出眼-肠轴的概念。但是肠菌和近视之间的具体关联仍然是一片空白。 在这项研究中，竺向佳、卢奕等人共招募来自上海高校的170名参与者，利用16S rRNA基因测序分析了高度近视患者（双眼眼轴长度≥ 26 mm）的肠道微生物群组成，并与健康对照组（眼轴长度22.00-24.50 mm）进行比较。 结果显示，高度近视患者的肠道微生物群组成发生了显著变化，与健康对照组相比Akkermansia、Fusobacteriaceae、Tissierellaceae、Parvimonas、TM7-3、Gemella和Carnobacteriaceae的定植减少，其中以益生菌Akkermansia的减少最为显著，而Pasteurellaceae、Gemmatimonadetes、Butyricicoccus和Lautropia的定植增加。 高度近视人群的菌群结构改变 双样本孟德尔随机化（MR）分析结果表明，Akkermansia与高度近视存在显著的因果关系，Akkermansia作为保护因子，其定植丰度与眼轴长度呈负相关。近视小鼠模型的粪菌移植实验也验证了这一点，恢复健康的肠道菌群可以减轻小鼠的近视进展，与接受高度近视患者粪便移植的小鼠相比，接受健康人群粪便移植的小鼠屈光不正减少34%，眼轴延长减少51.5%。 看来，眼睛和肠道菌群确实有着互动。 研究团队进一步利用代谢组学分析揭示了高度近视患者的血浆代谢物改变，发现肠菌衍生物3-IAA的减少最为明显，且3-IAA水平与眼轴长度呈负相关，与屈光不正呈正相关。与此结果相符，Akkermansia已被证明是3-IAA的主要生产者。 小鼠实验结果显示，接受健康人群粪便移植的小鼠3-IAA水平更高。更重要的是，对于近视小鼠模型，每日灌胃补充3-IAA可以将屈光不正减少51.9%，眼轴延长减少35.9%，还可有效减缓近视引发的巩膜I型胶原蛋白水平的下降。这些说明3-IAA在介导高度近视相关的眼-肠轴中扮演了关键角色，可以减缓高度近视的进展。 补充3-IAA缓解了小鼠近视 从机制来看，3-IAA能够增加转录因子SP1的表达，促进SP1在I型胶原蛋白α1链（COL1A1）编码基因的启动子区域富集和结合，从而上调COL1A1的转录和表达。 3-IAA保护视力的机制 实际上，不乏有大量研究对COL1A1的表达机制进行探索，但结果大多仅限于遗传因素，难以由此下手实施对高度近视的干预。 在这项研究中，竺向佳、卢奕等人关注高度近视与全身状态的潜在关联，并提出了一种新的思路，即高度近视的发展不仅是眼部的局部问题，还涉及肠道与眼部之间的复杂相互作用。这一发现让我们对高度近视相关的眼-肠轴有了更深一步了解，未来或可通过重塑肠道微生物群或补充特定代谢物如3-IAA，来延缓甚至逆转高度近视。

*仅供医学专业人士阅读参考 从小到大，为了防治近视，大家都说要保护用眼，可谁知道还有肚子里肠菌的事儿？ 复旦大学附属眼耳鼻喉科医院竺向佳、卢奕等人通过对高度近视患者的肠道微生物和代谢物进行深入分析，发现益生菌Akkermansia的定植以及肠菌代谢物吲哚-3-乙酸（3-IAA）的水平与近视的发展程度紧密相关。 他们利用小鼠实验揭示3-IAA可以促进巩膜中主要的结构蛋白质表达，即I型胶原蛋白，这意味着3-IAA有助于维持巩膜的结构完整性。每日补充3-IAA可以帮助高度近视小鼠阻止或减缓由于巩膜结构重构导致的近视进展，这为开发新型近视预防和治疗策略提供了可能。论文于近日刊登在Cell Discovery期刊上[1]。 论文首页截图 高度近视（HM）定义为等效球镜度数≤-6.00 D或眼轴长度（AL）≥ 26 mm，患者患青光眼、白内障、黄斑变性的风险较高。传统上人们往往只关注高度近视对眼睛本身的影响，比如视力下降和眼部结构的改变，而忽略了高度近视可能与身体其他系统功能失调之间的关系，这在很大程度上限制了寻找有效的干预措施。 巩膜中的细胞外基质（ECM）发生重塑，特别是关键成分I型胶原蛋白的改变，会削弱巩膜的结构框架，导致巩膜变薄和眼轴过度延长，从而诱发高度近视。正巧在过去二十年间，肠菌被发现对于多种疾病中的胶原蛋白重塑和纤维化有着显著影响，比如恢复健康肠菌可以防止小鼠的心脏过度纤维化，并在压力条件下恢复细胞外基质的完整性，或是特定类型肠菌的定植可以改善小鼠的肾脏纤维化。 因此，类似于脑-肠轴，已有研究提出眼-肠轴的概念。但是肠菌和近视之间的具体关联仍然是一片空白。 在这项研究中，竺向佳、卢奕等人共招募来自上海高校的170名参与者，利用16S rRNA基因测序分析了高度近视患者（双眼眼轴长度≥ 26 mm）的肠道微生物群组成，并与健康对照组（眼轴长度22.00-24.50 mm）进行比较。 结果显示，高度近视患者的肠道微生物群组成发生了显著变化，与健康对照组相比Akkermansia、Fusobacteriaceae、Tissierellaceae、Parvimonas、TM7-3、Gemella和Carnobacteriaceae的定植减少，其中以益生菌Akkermansia的减少最为显著，而Pasteurellaceae、Gemmatimonadetes、Butyricicoccus和Lautropia的定植增加。 高度近视人群的菌群结构改变 双样本孟德尔随机化（MR）分析结果表明，Akkermansia与高度近视存在显著的因果关系，Akkermansia作为保护因子，其定植丰度与眼轴长度呈负相关。近视小鼠模型的粪菌移植实验也验证了这一点，恢复健康的肠道菌群可以减轻小鼠的近视进展，与接受高度近视患者粪便移植的小鼠相比，接受健康人群粪便移植的小鼠屈光不正减少34%，眼轴延长减少51.5%。 看来，眼睛和肠道菌群确实有着互动。 研究团队进一步利用代谢组学分析揭示了高度近视患者的血浆代谢物改变，发现肠菌衍生物3-IAA的减少最为明显，且3-IAA水平与眼轴长度呈负相关，与屈光不正呈正相关。与此结果相符，Akkermansia已被证明是3-IAA的主要生产者。 小鼠实验结果显示，接受健康人群粪便移植的小鼠3-IAA水平更高。更重要的是，对于近视小鼠模型，每日灌胃补充3-IAA可以将屈光不正减少51.9%，眼轴延长减少35.9%，还可有效减缓近视引发的巩膜I型胶原蛋白水平的下降。这些说明3-IAA在介导高度近视相关的眼-肠轴中扮演了关键角色，可以减缓高度近视的进展。 补充3-IAA缓解了小鼠近视 从机制来看，3-IAA能够增加转录因子SP1的表达，促进SP1在I型胶原蛋白α1链（COL1A1）编码基因的启动子区域富集和结合，从而上调COL1A1的转录和表达。 3-IAA保护视力的机制 实际上，不乏有大量研究对COL1A1的表达机制进行探索，但结果大多仅限于遗传因素，难以由此下手实施对高度近视的干预。 在这项研究中，竺向佳、卢奕等人关注高度近视与全身状态的潜在关联，并提出了一种新的思路，即高度近视的发展不仅是眼部的局部问题，还涉及肠道与眼部之间的复杂相互作用。这一发现让我们对高度近视相关的眼-肠轴有了更深一步了解，未来或可通过重塑肠道微生物群或补充特定代谢物如3-IAA，来延缓甚至逆转高度近视。 奇点糕近期推出了《2024ASCO年会深度盘点》课程，为大家系统盘点了2024ASCO年会上实体瘤领域的重磅进展，让您在100分钟内迅速深入把握前沿。长按识别下图中的二维码即可购买，购买后您可以在「奇点网小程序」收听，或下载奇点网「医学奇点」苹果客户端收听。如果遇到任何技术问题大家可以戳我们下图中的客服小伙伴来解决~~ 参考文献： [1]https://www.nature.com/articles/s41421-024-00709-5 本文作者丨张艾迪